Maharashtra Herald

Axial Spondyloarthritis Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) – Evaluated by DelveInsight | Key Companies – UCB Biopharma, Celgene and Inmagene Biopharmaceuticals

 Breaking News
  • No posts were found

Axial Spondyloarthritis Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) – Evaluated by DelveInsight | Key Companies – UCB Biopharma, Celgene and Inmagene Biopharmaceuticals

October 19
18:51 2022
Axial Spondyloarthritis Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) - Evaluated by DelveInsight | Key Companies - UCB Biopharma, Celgene and Inmagene Biopharmaceuticals
The Axial Spondyloarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Axial Spondyloarthritis pipeline products will significantly revolutionize the Axial Spondyloarthritis market dynamics.

DelveInsight’s “Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Axial Spondyloarthritis, historical and forecasted epidemiology as well as the Axial Spondyloarthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Axial Spondyloarthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Axial Spondyloarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axial Spondyloarthritis Market Insights

 

Axial Spondyloarthritis Overview

Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition that consists of two subsets, which clinically have been defined as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

 

Some of the key facts of the Axial Spondyloarthritis Market Report: 

  • The Axial Spondyloarthritis market size was valued at USD 5,594.7 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • In the United States, ankylosing spondylitis is almost undiagnosed in roughly 50% of cases because of its mild course 
  • The total prevalent population of axSpA in the 7MM was 3,981,346 cases. These cases are anticipated to increase in during the forecast period [2022–2032] 
  • The highest prevalent cases of axSpA were accounted by the US in 2021, making up to 2,217,315 cases, while the EU5 countries accounted for 1,751,778 cases in the same year 
  • Key Axial Spondyloarthritis Companies: UCB Biopharma, Celgene and Inmagene Biopharmaceuticals, and others 
  • Key Axial Spondyloarthritis Therapies: Bimekizumab, CC-99677, ABY- 035, and others 
  • The Axial Spondyloarthritis epidemiology based in gender analyzed that the prevalent population of Axial Spondyloarthritis showed a male predominance, whereas, nr-axSpA showed female predominance 

 

Get a Free sample for the Axial Spondyloarthritis Market Report 

 

Key benefits of the Axial Spondyloarthritis Market report:

  1. Axial Spondyloarthritis market report covers a descriptive overview and comprehensive insight of the Axial Spondyloarthritis Epidemiology and Axial Spondyloarthritis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Axial Spondyloarthritis market report provides insights on the current and emerging therapies.
  3. Axial Spondyloarthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Axial Spondyloarthritis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Axial Spondyloarthritis market.

 

Download the report to understand which factors are driving Axial Spondyloarthritis epidemiology trends @ Axial Spondyloarthritis Epidemiological Insights 

 

Axial Spondyloarthritis Market  

The dynamics of the Axial Spondyloarthritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

“The entry of biosimilar in the market will increase the competition and might hinder both the approved and upcoming therapies if they are proven to be more effective and potential. It has also been observed that improved regulatory processes are also allowing the approval of biosimilars and making the process easier” 

 

Axial Spondyloarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Axial Spondyloarthritis Epidemiology Segmentation:

The Axial Spondyloarthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Axial Spondyloarthritis
  • Prevalent Cases of Axial Spondyloarthritis by severity
  • Gender-specific Prevalence of Axial Spondyloarthritis
  • Diagnosed Cases of Episodic and Chronic Axial Spondyloarthritis

 

Axial Spondyloarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axial Spondyloarthritis market or expected to get launched during the study period. The analysis covers Axial Spondyloarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Axial Spondyloarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Axial Spondyloarthritis market share @ Axial Spondyloarthritis market forecast 

 

Axial Spondyloarthritis Therapies and Key Companies

  • Bimekizumab: UCB Biopharma
  • CC-99677: Celgene
  • ABY- 035: Inmagene Biopharmaceuticals

 

Axial Spondyloarthritis Market Drivers

  • The introduction of novel products
  • Increasing Axial Spondyloarthritis prevalence
  • Awareness about the Disease
  • Research and development strategies

 

Scope of the Axial Spondyloarthritis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Axial Spondyloarthritis Companies: UCB Biopharma, Celgene and Inmagene Biopharmaceuticals, and others
  • Key Axial Spondyloarthritis Therapies: Bimekizumab, CC-99677, ABY- 035, and others
  • Axial Spondyloarthritis Therapeutic Assessment: Axial Spondyloarthritis current marketed and Axial Spondyloarthritis emerging therapies
  • Axial Spondyloarthritis Market Dynamics:  Axial Spondyloarthritis market drivers and Axial Spondyloarthritis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Axial Spondyloarthritis Unmet Needs, KOL’s views, Analyst’s views, Axial Spondyloarthritis Market Access and Reimbursement 

 

Axial Spondyloarthritis Market Barriers

  • High-cost Axial Spondyloarthritis treatment
  • Delay in Axial Spondyloarthritis Diagnosis
  • Immunogenicity
  • Loss of patent exclusivity
  • Availability of generics
  • Poor Quality of Life

 

Table of Contents 

1. Axial Spondyloarthritis Market Report Introduction

2. Executive Summary for Axial Spondyloarthritis

3. SWOT analysis of Axial Spondyloarthritis

4. Axial Spondyloarthritis Patient Share (%) Overview at a Glance

5. Axial Spondyloarthritis Market Overview at a Glance

6. Axial Spondyloarthritis Disease Background and Overview

7. Axial Spondyloarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Axial Spondyloarthritis 

9. Axial Spondyloarthritis Current Treatment and Medical Practices

10. Axial Spondyloarthritis Unmet Needs

11. Axial Spondyloarthritis Emerging Therapies

12. Axial Spondyloarthritis Market Outlook

13. Country-Wise Axial Spondyloarthritis Market Analysis (2019–2032)

14. Axial Spondyloarthritis Market Access and Reimbursement of Therapies

15. Axial Spondyloarthritis Market Drivers

16. Axial Spondyloarthritis Market Barriers

17.  Axial Spondyloarthritis Appendix

18. Axial Spondyloarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Axial Spondyloarthritis treatment, visit @ Axial Spondyloarthritis Medications

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market